FDA Approves Merck's DULERA(R) (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol for the Treatment of Asthma in Patients 12 Years of Age and Older WHITEHOUSE STATION, N.J., ...

The FDA has approved mometasone furoate and formoterol fumarate dihydrate inhalation aerosol for the treatment of asthma in patients aged 12 years and older.

Merck announced that the FDA has approved Dulera (mometasone furoate and formoterol fumarate dihydrate) inhalation aerosol for the treatment of asthma in patients ≥12 years of age.This approval ...

DULERA (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol is indicated for the treatment of asthma in patients 12 years and older. It is not indicated for the relief of ...

Schering-Plough announced that the FDA has approved Asmanex Twisthaler 110 mcg (mometasone furoate inhalation powder) for the maintenance treatment of asthma as a preventive therapy in patients 4 to ...

The FDA has approved Asmanex Twisthaler (mometasone furoate inhalation powder, from Schering-Plough) 110 mcg for the maintenance treatment of asthma as a preventive therapy in patients 4-11 years ...

ASMANEX 110 mcg has not been demonstrated to be effective in treating asthma symptoms caused by specific asthma triggers. The U.S. Food and Drug Administration (FDA) approved the use of ASMANEX ...

Mometasone furoate, 110 μg and 220 μg oral inhalation powders (Asmanex Twisthaler, Schering), is approved for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years ...

NEW YORK (MarketWatch) -- Schering-Plough Corp. lifted 27 cents, or 1.5 percent, to $27.29 in premarket trade Thursday after the U.S. Food & Drug Administration approved the Asmanex Twisthaler 220 ...

In many patients with mild, persistent asthma, the percentage of eosinophils in sputum is less than 2% (low eosinophil level). The appropriate treatment for these patients is unknown.In this 42-wee ...